Andreas Hochhaus,Thomas Schenk,Philipp Erben et al.
Andreas Hochhaus et al.
A minority of patients treated with imatinib are either refractory to imatinib or eventually relapse. Relapse frequently depends on re-emergence of BCR-ABL kinase activity but may also indicate BCR-ABL-independent disease progression. Over ...
Nicholas C P Cross
Nicholas C P Cross
Molecular monitoring of chronic myeloid leukaemia (CML) patients by real time quantitative reverse transcriptase PCR (RQ-PCR) is of clinical value, but the use of diverse laboratory protocols and units of measurement make it difficult to co...
Juan Carlos Hernández-Boluda,Francisco Cervantes
Juan Carlos Hernández-Boluda
Prognostic factors in patients with chronic myeloid leukaemia (CML) treated with conventional treatment include age, spleen size, platelet count, blood percentage of blasts, basophils and eosinophils, and cytogenetic abnormalities besides t...
Michele Baccarani,Fausto Castagnetti,Gabriele Gugliotta et al.
Michele Baccarani et al.
Imatinib is the standard front-line therapy of chronic myeloid leukaemia (CML). The evaluation of the response is based on blood counts and differential (haematologic response, HR), on the examination of marrow cell metaphases (cytogenetic ...
François Guilhot,Lydia Roy,Pierre-Jean Saulnier et al.
François Guilhot et al.
Imatinib has revolutionized the therapy of chronic myeloid leukaemia. However the complete eradication of leukaemic stem cells is still a matter of discussion. Interferon (IFN) has been used in the past with success. However the proportion ...
Treatment strategies for CML [0.03%]
CML的治疗策略
John M Goldman
John M Goldman
Little important progress was made in terms of prolongation of life for patients with chronic myeloid leukaemia (CML) until the advent of interferon-alpha and allogeneic stem cell transplantation in the 1980s. However, in 1998 the introduct...
Maren Rohrbacher,Joerg Hasford
Maren Rohrbacher
Reliable epidemiological information on chronic myeloproliferative disorders (CMPDs), notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukaemia (CML), is rare. Incidence rates vary from 0.6 to 2.0 cases per 100 000 inhabitants, i...
Daniela Cilloni,Giuseppe Saglio
Daniela Cilloni
The discovery of the Philadelphia (Ph) chromosome represented the first step towards understanding the molecular basis of haematological malignancies. Subsequent developments including the characterisation of t(9;22)(q34;q11) translocation,...
Richard Simon
Richard Simon
DNA microarrays are powerful tools for studying biological mechanisms and for developing prognostic and predictive classifiers for identifying the patients who require treatment and are best candidates for specific treatments. Because micro...